UroAlerts - Prostate Cancer Weekly

September 24, 2024

Videos

Peer-to-Peer Clinical Conversations

Tumor Suppressor Gene Signature Predicts Early Progression in mHSPC - Marta Garcia de Herreros

Marta Garcia de Herreros

Neeraj Agarwal interviews Marta Garcia de Herreros about presentation on tumor suppressor gene (TSG) signatures in metastatic hormone-sensitive prostate cancer (mHSPC).

Rising Out-of-Pocket Costs in Prostate Cancer Screening: A Growing Concern - Arnav Srivastava

Arnav Srivastava

Arnav Srivastava discusses his research on out-of-pocket costs for prostate cancer screening follow-up among privately insured men.

Beyond the Abstracts

Long Noncoding RNA EPCART Regulates Translation Through PI3K/AKT/mTOR Pathway and PDCD4 in Prostate Cancer - Beyond the Abstract

Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer - Beyond the Abstract

Conference Coverage

ESMO 2024: PSMA-targeted Radioligand Therapy with 131I-LNTH-1095 Plus Enzalutamide versus Enzalutamide Alone in Chemotherapy-naïve Patients Whose Piflufolastat F 18-avid Metastatic Castration-resistant Prostate Cancer Progressed on Abiraterone: ARROW

ESMO 2024: Final Safety and Efficacy Analysis of RaLu: 177Lu-PSMA Therapy in Patients with Prior Radium‑223

ESMO 2024: Association of the Lipid Biomarker, PCPro, and Clinical Outcomes in the ENZAMET Trial (ANZUP 1304)

ESMO 2024: Total and Regional Changes in Body Composition in Metastatic Hormone-Sensitive Prostate Cancer Patients Randomized to Receive Androgen Deprivation + Enzalutamide +/- Zoledronic Acid. the BonEnza Study

ESMO 2024: Prostate Cancer Working Group 4 Preliminary Criteria Using Serial PSMA PET/CT for Response Evaluation: Analysis from the PRINCE Trial

ESMO 2024: Opevesostat (MK-5684/ODM-208), an Oral CYP11A1 Inhibitor, in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Updated CYPIDES Phase 2 Results

ESMO 2024: Will Theranostics Become Standard of Care?

ESMO 2024: Are Cytotoxics Still the Next Option?

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Disparities in the Utilization of MRI for Prostate Cancer Detection: A Population-Based Study.

Whole-body MRI for staging prostate cancer: a narrative review.

Bipolar androgen therapy for treatment of metastatic castration-resistant prostate cancer: A case series.

Virtual reality as an adjunct to traditional patient counseling in patients with newly-diagnosed localized prostate cancer.

American Radium Society Appropriate Use Criteria for the Workup and Treatment of Local Intraprostatic Recurrence of Prostate Cancer Following Definitive Radiotherapy.

Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends.

A Machine Learning Approach for Predicting Biochemical Outcome After PSMA-PET-Guided Salvage Radiotherapy in Recurrent Prostate Cancer After Radical Prostatectomy: Retrospective Study.

Beyond Medical Bills: The Indirect Costs of Prostate Cancer.

Initial Experience with [177Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction.

Systemic treatments for advanced prostate cancer: relationship between health insurance plan and treatment costs.

Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for Advanced Disease States: A Systematic Review and Network Meta-analysis with Bayesian Modeling of Treatment Histories.

Does sexual rehabilitation work for gay and bisexual prostate cancer patients? Acceptability, feasibility, and efficacy results from the Restore-2 randomized controlled trial.

Comparison of Industry-Sponsored Trials (IST) and Investigator-Initiated Trials (IIT) in Advanced Genitourinary Cancers in the United States, Canada, United Kingdom and France.

Secondary Cancer in Prostate Cancer Patients Treated With Advanced External Beam Radiation Therapy.

5-α Reductase Inhibitors and Prostate Cancer Mortality - Beyond the Abstract

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.

Ipilimumab with Nivolumab in molecular-Selected patients with castration-resistant PRostate cancer: primary analysis of the Phase 2 INSPIRE trial.

Lipid Metabolism Modulatory Cisplatin Prodrug Sensitizes Resistant Prostate Cancer toward Androgen Deprivation Therapy.

Stereotactic radiotherapy for localized prostate cancer: 10-year outcomes from three prospective trials.

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study.

Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer.

A Common Culprit Drives Prostate Cancer Progression

Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer.

BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity.

Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer.

Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance.

Detection rate of gastrin-releasing peptide receptor (GRPr) targeted tracers for positron emission tomography (PET) imaging in primary prostate cancer: a systematic review and meta-analysis.

Prediction of undetectable circulating tumor DNA by comprehensive genomic profiling assay in metastatic prostate cancer: the SCRUM-Japan MONSTAR SCREEN project.

Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer.

Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201).

Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review.

Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing.

Safety profile of darolutamide versus placebo: a systematic review and meta-analysis.

West African Genetic Ancestry, Neighborhood Deprivation, and Prostate Cancer.

Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy.

Physician Perspectives on the Nonclinical Factors That Contribute to Decision-Making for Advanced Prostate Cancer Care: A Qualitative Study.

Evolving Paradigms in Prostate Cancer: The Integral Role of PSMA PET/CT in Primary Staging and Therapeutic Decision-Making.

Trifecta Outcomes After Use of 3-Dimensional Digital Models for Planning of Robotic Prostatectomy: A Secondary Analysis of a Randomized Clinical Trial.

Histopathology-validated gross tumor volume delineations of intraprostatic lesions using PSMA-positron emission tomography/multiparametric magnetic resonance imaging.

The polyunsaturated fatty acid docosahexaenoic affects mitochondrial function in prostate cancer cells.

CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.

A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer.

A Novel Artificial Intelligence-powered Tool for Precise Risk Stratification of Prostate Cancer Progression in Patients with Clinical Intermediate Risk.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC